226 related articles for article (PubMed ID: 10771080)
1. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.
Andrei G; Snoeck R; Neyts J; Sandvold ML; Myhren F; De Clercq E
Antiviral Res; 2000 Mar; 45(3):157-67. PubMed ID: 10771080
[TBL] [Abstract][Full Text] [Related]
2. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.
Hostetler KY; Rybak RJ; Beadle JR; Gardner MF; Aldern KA; Wright KN; Kern ER
Antivir Chem Chemother; 2001 Jan; 12(1):61-70. PubMed ID: 11437323
[TBL] [Abstract][Full Text] [Related]
4. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells.
Balzarini J; Degrève B; Andrei G; Neyts J; Sandvold M; Myhren F; de Clercq E
Gene Ther; 1998 Mar; 5(3):419-26. PubMed ID: 9614564
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
[TBL] [Abstract][Full Text] [Related]
6. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
7. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
Schott H; Hamprecht K; Schott S; Schott TC; Schwendener RA
Bioorg Med Chem; 2009 Jan; 17(1):303-10. PubMed ID: 19010684
[TBL] [Abstract][Full Text] [Related]
9. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.
Andrei G; Snoeck R; Reymen D; Liesnard C; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):318-29. PubMed ID: 7649195
[TBL] [Abstract][Full Text] [Related]
10. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.
Koyano S; Suzutani T; Yoshida I; Azuma M
Antimicrob Agents Chemother; 1996 Apr; 40(4):920-3. PubMed ID: 8849252
[TBL] [Abstract][Full Text] [Related]
11. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
Hamel W; Zirkel D; Mehdorn HM; Westphal M; Israel MA
Cancer Gene Ther; 2001 May; 8(5):388-96. PubMed ID: 11477459
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
13. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.
Shiota T; Lixin W; Takayama-Ito M; Iizuka I; Ogata M; Tsuji M; Nishimura H; Taniguchi S; Morikawa S; Kurane I; Mizuguchi M; Saijo M
Antiviral Res; 2011 Aug; 91(2):142-9. PubMed ID: 21669227
[TBL] [Abstract][Full Text] [Related]
14. Selection of HSV-1 TK gene-transfected murine mammary carcinoma cells resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV).
Degrève B; De Clercq E; Balzarini J
Gene Ther; 2000 Sep; 7(18):1543-52. PubMed ID: 11021592
[TBL] [Abstract][Full Text] [Related]
15. Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Snoeck R; Andrei G; De Clercq E
Eur J Clin Microbiol Infect Dis; 1996 Jul; 15(7):574-9. PubMed ID: 8874075
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
Bleymehl K; Cinatl J; Schmidt-Chanasit J
Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Ativiral Activity of 5-(Benzylthio)-4-carbamyl-1,2,3-triazoles Against Human Cytomegalovirus (CMV) and Varicella-zoster Virus (VZV).
Wen YN; Zhang ZF; Liu NN; Andrei G; Snoeck R; Xiang YH; Schols D; Chen X; Zhang ZY; Zhang QS; Wu QP
Med Chem; 2017; 13(5):453-464. PubMed ID: 28290250
[TBL] [Abstract][Full Text] [Related]
18. Analysis of antiviral drug properties of thymidine kinase of herpes B virus using recombinant herpes simplex virus 1.
Nguyen PHA; Fukushi S; Yamada S; Harada S; Yoshikawa T; Kinoshita H; Kawahara M; Ogawa T; Ebihara H; Moi ML; Saijo M
Microbiol Spectr; 2024 Jan; 12(1):e0309123. PubMed ID: 38095468
[TBL] [Abstract][Full Text] [Related]
19. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.
Freitas VR; Fraser-Smith EB; Matthews TR
Antiviral Res; 1989 Nov; 12(4):205-12. PubMed ID: 2559657
[TBL] [Abstract][Full Text] [Related]
20. Monitoring drug resistance for herpesviruses.
Andrei G; Fiten P; De Clercq E; Snoeck R; Opdenakker G
Methods Mol Med; 2000; 24():151-69. PubMed ID: 21331907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
